Marshall Wace
ADCT icon

Marshall Wace’s ADC Therapeutics ADCT Stock Holding History

Marshall Wace’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Buy
+45,479
New +$179K ﹤0.01% 2815
2025
Q4 		– Sell
-159,993
Closed -$640K – 2910
2025
Q3 		$640K Buy
+159,993
New +$504K ﹤0.01% 2135
2024
Q2 		– Sell
-243,243
Closed -$1.09M – 2493
2024
Q1 		$1.09M Buy
243,243
+221,395
+1,013% +$817K ﹤0.01% 1618
2023
Q4 		$36.3K Sell
21,848
-416,825
-95% -$385K ﹤0.01% 2086
2023
Q3 		$395K Buy
438,673
+73,615
+20% +$97.9K ﹤0.01% 1793
2023
Q2 		$785K Buy
365,058
+207,379
+132% +$466K ﹤0.01% 1825
2023
Q1 		$307K Buy
+157,679
New +$582K ﹤0.01% 2287
2021
Q1 		– Sell
-59,567
Closed -$1.91M – 2416
2020
Q4 		$1.91M Sell
59,567
-136,085
-70% -$4.46M 0.01% 970
2020
Q3 		$6.46M Buy
+195,652
New +$8.47M 0.04% 432

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace's ADCT Position: Q1 2026 in Review

Marshall Wace opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 45,479 shares worth $171K. The stake represents ﹤0.01% of the portfolio and ranks #2815 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ADCT as recently as Q3 2025.

Marshall Wace first reported a position in ADCT in Q3 2020 and has held it in 9 quarters since. The position peaked at $6.46M in Q3 2020. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Marshall Wace held 45,479 shares of ADC Therapeutics worth $171K as of Q1 2026.
  • ADC Therapeutics was a new Marshall Wace position in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2815 holding.
  • Marshall Wace first reported a position in ADC Therapeutics in Q3 2020 and has held it in 9 quarters since.
  • Marshall Wace's ADC Therapeutics position peaked at $6.46M in Q3 2020.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.